Rate Video

iwMyeloma 2015 | Novel HDAC6 inhibitor, ricolinostat, for the treatment of multiple myeloma

Noopur Raje • 11 Apr 2015

iwMyeloma 2015

Multiple Myeloma

At the Myeloma 2015 meeting, Dr Noopur Raje (Massachusetts General Hospital, Boston, MA) discusses the clinical development of the selective histone deacetylase 6 (HDAC6) inhibitor, ricolinostat, for the treatment of multiple myeloma. Clinical results to date suggest that ricolinostat is likely to operate synergistically with other agents.

Trial updates in R/R MM from ASCO: ARROW, MMY1001 & OPTIMISMM

Noopur Raje • 1 Jun 2018

Results of Phase Ib/II study of ricolinostat in multiple myeloma

Noopur Raje • 9 Jun 2016

Myeloma at ASH 2020: what to expect?

Noopur Raje • 23 Nov 2020

CAR-T and cellular therapy at ASH 2020

Noopur Raje • 23 Nov 2020

Related Videos

A.R.R.O.W. study: carfilzomib dosing in frail MM patients

Maria-Victoria Mateos

Managing CRS in myeloma

Managing transplant patients during the COVID-19 pandemic

Christian Chabannon

DNA methyltransferase inhibitors: daratumumab enhancement for MM